Capricor Therapeutics
CAPR
30 hedge funds and large institutions have $10.1M invested in Capricor Therapeutics in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 7 closing their positions.
89% more call options, than puts
Call options by funds: $739K | Put options by funds: $390K
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
2% more capital invested
Capital invested by funds: $9.94M → $10.1M (+$203K)
1.22% less ownership
Funds ownership: 10.85% → 9.63% (-1.2%)
3% less funds holding
Funds holding: 31 → 30 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$129K |
| 2 |
VF
Virtu Financial
New York
|
+$72.7K |
| 3 |
Charles Schwab
San Francisco,
California
|
+$58K |
| 4 |
Renaissance Technologies
New York
|
+$32.3K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$24K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$407K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$280K |
| 3 |
Millennium Management
New York
|
-$204K |
| 4 |
BlackRock
New York
|
-$193K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$113K |
CAPR Hedge Fund Activity: Q1 2023 in Review
30 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q1 2023, worth a combined $10.1M — up 2% from $9.94M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of CAPR and 6 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 9 added.
The largest buyer was Commonwealth Equity Services, opening a new position worth an estimated $129K. The largest seller was Susquehanna International Group, cutting an estimated $407K.
- 30 institutional investors held Capricor Therapeutics (CAPR) as of Q1 2023, down from 31 in Q4 2022.
- Funds reported $10.1M of Capricor Therapeutics stock for Q1 2023, up 2% quarter-over-quarter.
- 6 funds opened new Capricor Therapeutics positions in Q1 2023 and 7 closed out, a net change of -1 holder.
- The largest Capricor Therapeutics buyer in Q1 2023 was Commonwealth Equity Services, an estimated $129K added.
- The largest Capricor Therapeutics seller in Q1 2023 was Susquehanna International Group, an estimated $407K sold.
Based on aggregated 13F filings for Q1 2023.